Top Digital Biomarkers Companies

Global Digital Biomarkers Market size was valued at USD 5.02 Billion in 2024 and is poised to grow from USD 6.47 Billion in 2025 to USD 48.97 Billion by 2033, growing at a CAGR of 28.8% during the forecast period (2026–2033). 

The global digital biomarkers market outlook is characterized by rapid technical breakthroughs, intense rivalry, and new investment. Companies in this sector are directing their attention to partnerships, collaborations, innovative products, and mergers and acquisitions to obtain a competitive advantage. Companies are investing in R&D to produce new, advanced products with the most modern features and capabilities. 'BioSensics (United States) ', 'AliveCor (United States) ', 'BACtrack (United States) ', 'Eyenuk (United States) ', 'Quibim (Spain) ', 'Biofourmis (United States) ', 'Fitbit (United States) ', 'Evidation Health (United States) ', 'Empatica (United States) ', 'Philips Healthcare (Netherlands) ', 'Medtronic (Ireland) ', 'Akili Interactive (United States) ', 'Apple Inc. (United States) ', 'Biotricity (United States) ', 'Tempus (United States) ', 'Pear Therapeutics (United States) ', 'BioBeats (United Kingdom) ', 'Oura Health (Finland) ', 'ActiGraph (United States) ', 'Koneksa (United States)'

The incidence of diabetes, hypertension, and cardiovascular conditions continues to escalate and underlines the growing demand for digital biomarkers. Digital biomarkers offer crucial information that ensures immediate reaction and uninterrupted monitoring by healthcare systems towards chronic illnesses. It encourages best management practices that allow patients to stay healthy for longer periods and to be hospitalized fewer times, thus contributing toward improved quality of life while reducing healthcare expenditure. 

Integration of AI: One of the major digital biomarkers market trends is the integration of AI. It may be that all wearables and health application-generated data could end up processed by AI algorithms and result in patterns and insights that doctors might not immediately identify. That said, however, this trend enables more proactive and individualized approaches to healthcare, better management of an illness, and better results by improving the predictive power of the digital biomarkers. 

North America secured the highest digital biomarkers Digital Biomarkers Market share in 2023 at 58.4% compared to other markets, leading to increased R&D spending, the presence of major market players, growing acceptance of smart devices, major product launches, and the growing knowledge of the efficacy of digital biomarkers in that region. The market is also expanding due to the growing number of programs encouraging healthcare infrastructure construction. The Digital Biomarker Summit USA, organized in Tarrytown, New York, by the Digital Biomarkers Summit USA event in May 2024, featured and presented key notes and a discussion on the topic: digital biomarkers in clinical trials, bringing instances with wearable technology that provide aspects of AI integration. In addition, digital phenotyping and how this affects observational research was investigated. It has also focused on new innovations and improvements in regulatory preparedness to embrace these cutting-edge endpoint measurement techniques. These are expected to sustain a high requirement of uptake and breadth of digital biomarker in the region.